Previous Close | 37.13 |
Open | 37.27 |
Bid | 37.05 x 100 |
Ask | 37.33 x 100 |
Day's Range | 37.06 - 38.14 |
52 Week Range | 17.53 - 45.68 |
Volume | |
Avg. Volume | 911,553 |
Market Cap | 2.853B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.69 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 33.64 |
Director Jerome Zeldis of PTC Therapeutics Inc (NASDAQ:PTCT) executed a sale of 20,000 shares of the company on May 22, 2024, according to a recent SEC Filing.
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.